GlaxoSmithKline Pharmaceuticals Limited (GSK) today announced its financial results for quarter ended June 30, 2024. Revenue from operations for the quarter grew by 10% at Rs. 811 crores. Profit After Tax (PAT) for the quarter at Rs. 182 crores.

The company continued to deliver a strong growth of 10% with key brands such as Calpol, Augmentin, T-Bact and gaining market share. In addition, the Respiratory portfolio comprising Nucala and Trelegy delivered a growth of 57% by further improving access to more patients.

The Paediatric vaccine segment maintained market leadership in the self-pay private market and delivered double-digit growth of 15%. In the Adult vaccines segment, GSK continues to build on the momentum from the launch of Shingrix Herpes Zoster Vaccine (recombinant, adjuvanted) to further expand the Adult Immunisation category in India through its innovative go-to-market (GTM) strategies.

Commenting on the results, Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said “We continue our growth momentum across General Medicines and Vaccines portfolios while maintaining profitability. As we celebrate hundred years of our operations in India, we remain committed to pursuing new growth opportunities, enhancing our leadership in key therapeutic areas and advancing our innovative omnichannel strategies to further enhance customer experience.”